Journal editors question sale of diet pill Meridia

Sep 01, 2010 By STEPHANIE NANO , Associated Press Writer

(AP) -- Editors of a top medical journal are questioning whether the diet pill Meridia should stay on the market even if it's restricted to people without heart disease.

A new study shows the appetite suppressant raises the risk of and stroke in people with heart problems.

The strongly worded editorial in Thursday's comes two weeks before government advisers review the prescription drug.

The weight-loss pill has already been pulled in Europe and U.S. drug regulators have added stronger warnings to the label.

The maker of the diet pill, Abbott Laboratories, says it's still appropriate for obese people who don't have and who can't lose weight through diet and exercise.

Explore further: Drug research and development more efficient than expected

2 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

Health Canada warns against Meridia

Oct 16, 2007

Health Canada issued a warning for doctors not to prescribe the weight loss drug Meridia to people who may be at risk of serious heart-related side effects.

FDA to review first of 3 new weight loss drugs

Jul 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

FDA panel rejects experimental weight loss pill

Jul 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

Pill claims weight loss with no diet

Oct 08, 2007

Akavar 20/50, a pill produced in Salt Lake City, has become the most recent product to advertise weight loss with no diet or exercise.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.